Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Halberd Corp HALB

Halberd Corp is focused on the research and development of pharmaceutical products for the treatment of diseases such as Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer's Disease, Blood Sepsis, Atherosclerosis, and Cancer.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Halberd Creates Subsidiary to Apply Its Patented Technology

JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) more

Halberd Corp. & Mississippi State University Discuss Animal

JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore more

Halberd Successfully Eliminates Excess Levels

Halberd's researchers successfully reduced the level of Interleukin-4 (IL-4) in a mixture of IL-4 and Interleukin-6 (IL-6) in vitro to a predetermined level without significantly reducing more

Halberd Engages Professional Firm to Proceed with FDA Filing

JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the more

Halberd Submits Audited Financials; Files Form-10 as First

Jackson Center, Pennsylvania--(Newsfile Corp. - May 12, 2022) - Halberd Corporation (OTC Pink: HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC more

Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorp

JACKSON CENTER, PA / ACCESSWIRE / April 29, 2022 / A key member of Halberd Corporation's (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® more

Halberd CEO Letter

Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases. Halberd demonstrated that its more

Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days

JACKSON CENTER, PA / ACCESSWIRE / April 18, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication more

Halberd Entering the Medical Metaverse(TM)

Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in non-fungible tokens (NFT's) who can identify growth opportunities by monitoring the more

Halberd Continues In-Vitro Successes With Elimination

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "In patients with major clinical depression, numerous peer reviewed more

Infectious Disease Specialist Will Guide Halberd's Extracorp

JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation (OTC PINK:HALB) announces its entry into the next stage of research. To guide it, having successfully more

Halberd Expands Its Technical Expertise with the Addition

Dr. Cooper earned his Doctorate and Master Degrees in Microbiology at the University of Texas - Austin in 1989, and 1983, respectively. In addition to his role as Professor, Dr. Cooper is active more

$HALB Halberd's COVID-19 Antibody is the Only One

JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the more

Halberd Medical Breakthrough for the Treatment of Neurodegen

JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With more

Halberd Eliminates 100% of Tau Protein From CSF - The 9th

The company also completed duplication tests on the elimination of 100% of the cytokine Interleukin-4 (IL-4) as initially reported in preliminary tests in a previous announcement. Dr. Mitchell more

Halberd Achieves Landmark Selective Elimination of Tau

JACKSON CENTER, PA / ACCESSWIRE / February 1, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to selectively reduce and control the level of one element in more

Halberd CEO Letter: 2021 Year-End & 2022 Outlook

2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is a huge worldwide demand for cures to long standing diseases; There more

Halberd, Inc. (HALB) Reports Elimination of Target Antigens,

Dr. Mitchell S. Felder, HALB's Chief Technology Officer and a board-certified attending neurologist stated, "Beta-Amyloid is widely recognized to be a major factor of Alzheimer's more

Halberd Corporation Now an Official US Government Contractor

JACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government's System for Award Management allowing more

Halberd Moves Closer to Proving Its Patented Technologies

JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral more